Latest News
  • iGene will be at the 10th SICOG 2015 at Singapore.


With highly-accurate results at an early stage of pregnancy, the patient has
sufficient time to make informed choices in the event of a positive test.

If a decision is then made to undergo invasive diagnostic testing,
iGeneCares™ offers a reimbursement of up to US$400 towards this.


How Does Non-Invasive Prenatal Testing Work?


As the baby develops, cell free DNA (cfDNA) enter the mother's blood stream via the placenta. iGene™ involves taking a small sample of maternal blood, which is then sent to our laboratory for analysis.

iGene™ is based on whole genome sequencing coupled with BGl's proprietary bioinformatics algorithm. Millions of reads from sequencing data across the genome are analysed to enhance the precision and accuracy of the test results.

Share
Source:

1 Dan, S. et al. Prenat Diagn 2012, 32(13), 1225-32. 2. BGI Clinical Laboratories Data, 2013. 3. Lewis, C. et al. Public Health Genomics 2013.

What We Test


iGene™ provides superior accuracy for the screening of Trisomy 21, 18, 13, sex chromosome aneuploidies and deletion syndromes. iGene™ is suitable for at-risk expectant mothers who may be considering, or have been offered, invasive prenatal diagnostic testing for fetal trisomy.


While the iGene™ test can be done as early as 10 weeks, we recommend waiting till the 12th week, when the pregnancy is more stable.


View what a mother has to say about our test:

Comparisons with Current Screening Technologies


The detection rates of the currently available screening tests vary from less than 70% to 84%, implying that between
16% to over 30% of abnormal fetuses are not detected. Using advanced Next Generation Sequencing technology,
iGene™ is 99.96% accurate, compared with these existing screening tests1,2,3.


DETECTION RATE

This is the rate at which correct detections of chromosomal abnormalities are made.

FALSE POSITIVE RATE

This is when the test comes back positive when in fact there is no abnormality present. Learn More

FALSE NEGATIVE RATE

This is when the test comes back negative when in fact an abnomality does exist.


LEGEND: IGENE™ 1ST TRIMESTER NUCHAL TRANSLUCENCY TRIPLE TEST


An explanation of the different types of screening technologies

Source 1.Dan et al., Prenatal Diagnosis 2012;32;1-8. 2. BGI Clinical Laboratories Data, 2013. 3. Lewis, C. et al. Public Health Genomics 2013. 4. Bianchi et al. 2014. The New England Journal of Medicine, 2014 Feb, 370:799-808.

Click the links below to find out more

Stay updated on iGene™ and receive
our white papers in your inbox:

Connect with us on Facebook



Look Up Word